5650-52-2

Usage

Uses

Used in Pharmaceutical Industry:
4,5-Dihydrocyclopenta[b]thiophen-6-one is utilized as a chemical intermediate for the synthesis of various pharmaceuticals. Its distinctive structure and reactivity contribute to the development of new drugs, making it an essential component in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4,5-Dihydrocyclopenta[b]thiophen-6-one serves as a key intermediate in the production of agrochemicals. Its role in creating effective and novel compounds for agricultural applications underscores its importance in this field.
Used in Fragrance Industry:
4,5-Dihydrocyclopenta[b]thiophen-6-one is employed as a flavoring agent in food products, capitalizing on its ability to impart unique and desirable flavors. This application highlights its versatility and significance in the food and flavor industry.
Used in Organic Synthesis:
4,5-Dihydrocyclopenta[b]thiophen-6-one's diverse range of applications extends to its use as a building block in organic synthesis. Its capacity to easily undergo chemical reactions makes it a versatile and important compound across various chemical industries.

InChI:InChI=1/C7H6OS/c8-6-2-1-5-3-4-9-7(5)6/h3-4H,1-2H2

Upstream product

• 26359-23-9 3-thienylpropionic acid chloride 
• 121792-93-6 2,3-Dibromo-4,5-dihydro-cyclopenta[b]thiophen-6-one 
• 16378-06-6 3-(3-thienyl)propanoic acid 
• 21980-45-0 1-(thiophen-2-yl)-3-(trimethylsilyl)prop-2-yn-1-ol 
• 98-03-3 thiophene-2-carbaldehyde 
• 1195-52-4 3-(3-thienyl)-2-propenoic acid 
• 1195-52-4 trans-3-(3-thienyl)acrylic acid 
• 34846-44-1 3-Bromomethylthiophene 
• 616-44-4 3-Methylthiophene 
• 26415-26-9 [3]thienylmethyl-malonic acid 
• 26415-25-8 3-thiophen-3-yl methyl malonic acid diethyl ester 
• 13191-36-1 2,5-dibromo-3-methylthiophene 
• 121792-91-4 <2,5-Dibrom-3-thenyl>-malonsaeurediethylester 
• 13191-37-2 2,5-dibromo-3-bromomethylthiophene 

Downstream Products

• 13196-30-0 4,5-dihydro-5-methyl-6H-cyclopentathiophen-6-one 
• 827609-16-5 (R)-5-hydroxy-4,5-dihydro-6H-cyclopenta[b]thiophen-6-one 
• 827609-18-7 (S)-5-hydroxy-4,5-dihydro-6H-cyclopenta[b]thiophen-6-one 
• 126983-09-3 6-[2-(Aminomethyl)-phenyl]-4H-cyclopenta[b]thiophene 
• 126983-11-7 [2-(4H-Cyclopenta[b]thiophen-6-yl)-benzyl]-carbamic acid 2,2,2-trichloro-ethyl ester 
• 827609-12-1 (5S,2S)-6-oxo-5,6-dihydro-4H-cyclopenta[b]thien-5-yl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate 
• 827609-11-0 (5R,2S)-6-oxo-5,6-dihydro-4H-cyclopenta[b]thien-5-yl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate 
• 1026640-09-4 (5R,2S)-5-methyl-6-oxo-5,6-dihydro-4H-cyclopenta[b]thien-5-yl 2-amino-3-phenylpropanoate 
• 827609-27-8 N-[(5R,6R)-5-hydroxy-5,6-dihydro-4H-cyclopenta[b]thiophen-6-yl]-2-isopropylbenzenecarboxamide 
• 827609-26-7 N-[(5R,6R)-5-hydroxy-5,6-dihydro-4H-cyclopenta[b]thiophen-6-yl]-2,6-dimethylbenzenecarboxamide 

Relevant academic research and scientific papers

Control of the Bandgap of Conducting Polymers by Rigidification of the ?-Conjugated System

Rigidification of E-1,2(2,2'-dithienylethylene) by bridging the thiophene rings with the central double bond leads to a ca. 0.40 eV decrease of the bandgap of the resulting conducting polymer.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Intramolecular Friedel-Crafts Acylation Reaction Promoted by 1,1,1,3,3,3-Hexafluoro-2-propanol

Simple dissolution of an arylalkyl acid chloride in 1,1,1,3,3,3-hexafluoro-2-propanol promotes an intramolecular Friedel-Crafts acylation without additional catalysts or reagents. This reaction is operationally trivial in both execution and product isolation (only requiring concentration followed by purification) and accommodates a broad range of substrates. Preliminary studies that bear upon potential reaction mechanisms are reported.

Fused thiophene-based conjugated polymers and their use in optoelectronic devices

The present teachings relate to certain polymeric compounds and their use as organic semiconductors in organic and hybrid optical, optoelectronic, and/or electronic devices such as photovoltaic cells, light emitting diodes, light emitting transistors, and field effect transistors. The disclosed compounds can provide improved device performance, for example, as measured by power conversion efficiency, fill factor, open circuit voltage, field-effect mobility, on/off current ratios, and/or air stability when used in photovoltaic cells or transistors. The disclosed compounds can have good solubility in common solvents enabling device fabrication via solution processes.

Pharmaceutical compounds wiht angiogenesis inbhibitory activity

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A' are as defined in the description. B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3-, SO3H, COO-, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

PHARMACEUTICAL COMPOUNDS

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A′ are as defined in the description.B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3?, SO3H, COO?, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

MST1 KINASE INHIBITORS AND METHODS OF THEIR USE

Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.

Rh(I)-catalyzed cyclization of 1-arylprop-2-yn-1-ol derivatives utilizing rhodium 1,4-migration

A highly useful method for the construction of cyclopentanone derivatives fused with aromatic ring based on hydrorhodation-1,4-rhodium migration sequence is achieved. Treatment of 1-aryl-prop-2-yn-1-ols, which are easily accessible via an addition of acetylides to the corresponding aryl aldehydes, with a catalytic amount of [Rh(cod)2]2(BF4) and P(p-tolyl)3 in the presence of a base gives cyclopentanone derivatives in moderate to good yield. Copyright

Diastereoselective synthesis of thieno[3′,2′:4,5]cyclopenta[1, 2-d][1,3]-oxazolines - New ligands for the copper-catalyzed asymmetric conjugate addition of diethylzinc to enones

Several new ligands featuring a rigid three ring skeleton have been prepared for the first time following a modular approach. Chirality has been introduced by use of an oxazoline moiety fused with a cyclopenta[b]thiophene backbone. The efficiency and stereochemical impact of these ligands on the copper-catalyzed enantioselective addition of Et2Zn to chalcone was examined and enantiomeric excesses up to 79% were achieved using the ligand (R,R)-16 substituted with a methyl group at the cyclopenta moiety. Computational and ESI-mass spectral studies show that these new compounds behave as monodentate ligands towards Cu+. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.